Fellowship Program Overview
The Dr. Stephen A. Harrison Patient Advocacy Fellowship Program is a pioneering initiative designed to elevate the role of patient advocates in MASH (Metabolic Dysfunction-Associated Steatohepatitis) and steatotic liver disease research, drug and diagnostic development, and policy discussions.
This annual fellowship empowers up to 20 patient advocates by providing financial support, education, and access to key scientific and policy forums where they can contribute meaningfully to shaping the future of liver disease care.
Why This Program?
Despite significant advancements in MASH research, the patient voice remains underrepresented in clinical trial design, regulatory decision-making, and policy development. This fellowship was created to:
- Empower patient advocates with clinical trials literacy and policy knowledge
- Bridge the gap between patients, researchers, and industry leaders
- Ensure treatments align with the real-world experiences of those living with MASH and steatotic liver disease
- Support participation in national and global conferences, ensuring patient perspectives inform research and drug development
Honoring the Legacy of Dr. Stephen A. Harrison
Dr. Stephen A. Harrison was a world-renowned clinician, researcher, and advocate whose work transformed how we understand and treat steatotic liver disease. He believed that patients should be equal partners in research and clinical innovation, and this Fellowship carries forward that vision.
“This Fellowship honors Dr. Harrison’s legacy as a world-class clinician and tireless advocate for putting patients at the center of liver disease research. We are not just launching a program; we are building a movement that bridges science and lived experience.”
— Wayne Eskridge, Founder and CEO, Fatty Liver Foundation“Dr. Harrison was a visionary, and it was a privilege to work alongside him throughout the resmetirom development journey. This fellowship is a meaningful way to carry forward his commitment to patients, science, and the future of liver health.”
— Dr. Rebecca Taub, Founder and Senior Scientific and Medical Advisor, Madrigal Pharmaceuticals